

May 7, 2025
Fuji Pharma Co., Ltd.

Fuji Pharma Receives SBTi (Science Based Targets initiative) Approval

Fuji Pharma Co., Ltd. (Head Office: Tokyo, Japan; President and CEO: Shuhei Morita) announced today that it has received SBTi (Science Based Targets initiative) ※1 approval for the greenhouse gas (GHG) emissions reductions targets of Fuji Pharma Group by fiscal 2030 in line with 1.5°C scenarios.



【GHG emissions reductions targets ※2】

- Reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year.
- Reduce absolute Scope 3 GHG emissions from purchased goods and services 25% by FY2030 from a FY2022 base year.

Fuji Pharma and subsidiary, OLIC (Thailand) Limited, are implementing renewable energy to become carbon neutral by 2050.

We will continue to contribute to the realization of a decarbonized society and the sustainable development of local communities by GHG emissions as part of our ongoing efforts to conduct environmentally friendly business activities.

※1 SBTi (The Science Based Targets initiative) is a collaboration between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF).

The SBTi defines and promotes best practice in science-based target setting and independently assesses companies' targets.

※2 Scope 1: Direct emissions by business operators

Scope 2: Indirect emissions from the use of electricity supplied by other companies

Scope 3: All indirect emissions other than Scope 2

For more information on Fuji Pharma's Sustainability Management and environmental initiatives, please visit the company's website.

<https://www.fujipharma.jp/sustainability/>

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp